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Abstract
The primary objective of this study was to evaluate the safety and the effect of D-tagatose on the 
glycemic control of subjects with type 2 diabetes as determined by HbA1c levels at the end of 6 months of 
therapy using the subject’s own baseline HbA1c level as a comparator. The determination of the minimal dose 
required to cause a statistically significant reduction in HbA1c was of particular interest. Eight weeks after 
screening, the qualifying subjects were randomized to receive one of three doses of D-tagatose: 2.5 g TID, 
5.0 g TID or 7.5 g TID. Blood levels of HbA1c, fasting blood glucose concentrations, plasma lipids, changes in 
body weight, changes in body mass index, and change in insulin levels were checked at each study visit and 
at the end of the study. Treatment success, as measured by the reduction of HbA1c, was greatest for the 7.5 g 
D-tagatose dose group, although the difference between the treatments was not statistically significant. For 
fasting glucose, only the 7.5 g dosage group exhibited reductions from baseline at the 3- and 6-month time 
points. Mean body weights reduced in a dose-response fashion, with the 5.0 g and the 7.5 g D-tagatose 
doses providing the greatest reductions. D-tagatose at dosages of 2.5 g, 5.0 g, and 7.5 g TID for six months 
were well tolerated by this subject population. D-tagatose at 5.0 g TID was the minimal dose required to 
reduce HbA1c. D-tagatose at 7.5 g TID provided the greatest effect in most measured efficacy parameters. 
ABBREVIATIONS
AE - Adverse event; EE - Efficacy evaluable; GRAS - Generally 
recognized as safe; HbA1c - Glycosylated hemoglobin A1c; HDL - 
High-density lipoprotein; ITT - Intent-to-treat; LDL - Low density 
lipoprotein; SAE - Serious adverse event; TID - three times daily; 
VLDL - Very low density lipoprotein.
INTRODUCTION
Peripheral insulin resistance and progressive failure 
of pancreatic β-cell function leading to inadequate insulin 
secretion are the two principal abnormalities that characterize 
the pathogenesis of type 2 diabetes [1]. Early intervention at 
the onset of type 2 diabetes generally consists of maintaining a 
proper diet and weight, along with regular exercise. If control 
of blood glucose deteriorates further, then pharmacological 
intervention with one or more oral anti-diabetic agents is 
required. Unfortunately for many, type 2 diabetes will continue 
to progress and exogenous insulin treatment as primary therapy 
with oral anti-diabetic agents as adjunctive therapy are required 
in order to achieve glycemic control.  Treatment with insulin 
is usually a point of no return for these patients and a major 
treatment goal is to prevent progression to this point. Despite all 
of these interventions including insulin and the introduction of 
a number of novel agents for the treatment of type 2 diabetes in 
recent years, glucose control for many remains unsatisfactory. 
Recently, a review that included 140 controlled trials and 26 
observational studies comparing diabetes medications, both as 
monotherapy and in two-drug combinations, concluded that there 
was not enough evidence to clearly support the use of one drug or 
drug combination over another for stemming the complications 
of diabetes, including macrovascular and microvascular 
complications and mortality [2]. Metformin, a drug introduced in 
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the United States in 1994 and as early as 1958 in other countries, 
is still the most common first drug of choice for the treatment of 
type 2 diabetes.  Compared to the newer drugs, metformin is the 
drug that has the highest benefit-to-risk ratio for intermediate 
outcomes, such as HbA1c reduction, less weight gain and less risk 
of hypoglycemia. However, no currently available therapy has 
been shown to slow the decline in β-cell function in established 
type 2 diabetes. Even with aggressive intervention, it is estimated 
that 60% of diabetics don’t achieve target blood sugar levels with 
their current treatment [3]. Moreover, particular drugs available 
for treatment of diabetes may result in unwanted weight gain 
(long and rapid acting insulin, sulfonylureas, thiazolidinediones, 
repaglinide, nateglinide), hypoglycemia (insulin, sulfonylureas), 
gastrointestinal distress (metformin, α-glucosidase inhibitor, 
amylin mimetics, bile acid sequestrant, bromocriptine), or more 
serious adverse events such as pancreatitis (short and long-
acting glucagon-like peptide-1(GLP-1) agonists and dipeptidyl 
peptidase-4 (DDP-4) inhibitors) [4,5]. These findings illustrate 
the limitations of drug therapies currently available for the 
progression of diabetes. 
The observation that many diabetics are not able to con-
sistently control their blood sugar levels within recommended 
limits using the best available treatments, uncovers the serious 
need for a drug that can slow and/or halt the progression of dia-
betes. Preferably, such a drug should exhibit a unique mode of 
action to enable additive or synergistic use with current thera-
pies; produce no weight gain, hypoglycemia, or other limiting or 
unmanageable side effects; preserve or enhance β-cell function; 
and reduce cardiovascular risk factors that lead to morbidity and 
mortality.
D-tagatose is an isomer of fructose and is ~90% as sweet as 
sucrose, or sugar. D-tagatose was designated in 2001 as a Gener-
ally Recognized as Safe (GRAS) product by the United States Food 
and Drug Administration and is used as a nutritive or low-calorie 
sweetener [6,7]. Currently, D-tagatose may be used as a sweet-
ener in diet beverages, light ice creams or yogurts, and regular or 
dietetic hard candies [Rulis Agency response letter GRAS notice]. 
Preliminary animal and pre-clinical studies of D-tagatose have 
demonstrated its ability to lower blood glucose and lipoprotein 
levels. When consumed, D-tagatose functions as a “sugar blocker” 
by inhibiting lipid formation from carbohydrates without stimu-
lation of pancreatic beta cells for insulin production or secretion 
[7]. Regarding lipoprotein levels, D-tagatose has been shown to 
reduce total cholesterol and VLDL and LDL-cholesterol when 
compared to sucrose [8], and increase HDL-cholesterol levels 
[9].  A number of clinical trials demonstrating the ability of D-
tagatose to blunt postprandial rises in blood glucose and reduce 
HbA1c have been conducted on healthy subjects and diabetic pa-
tients [10-16]. Single-dose and repeated-dose studies in healthy 
and diabetic human subjects have shown that the predominant 
adverse effects associated with excessive consumption of D-
tagatose are gastrointestinal disturbances attributed to osmotic 
effects from incompletely absorbed D-tagatose [10-16]. Such 
effects are also commonly associated with excessive consump-
tion of other poorly digestible carbohydrates including polyols. 
Therefore, D-tagatose shows promise in multiple clinical appli-
cations, including the treatment of diabetes. In short, D-tagatose 
provides glycemic and lipoprotein control through a mechanism 
of action unlike any agent that is currently available on the mar-
ket in the United States.
The primary objective of this study was to evaluate the ef-
fect of three low-doses of D-tagatose on the glycemic control of 
subjects with type 2 diabetes. The purpose was to determine the 
minimum dose able to reduce HbA1c. The secondary objectives 
were to evaluate the effect of these three doses of D-tagatose 
compared to the subject’s own baseline levels for 
 • HbA1c at each study visit 
 • fasting plasma glucose 
 • fasting lipid profiles 
 • insulin concentration 
 • changes in body weight
 • the number of subjects requiring additional anti-diabetic 
medications and/or withdrawal from the study due to 
high glycemic measurements 
In addition, the safety of D-tagatose in regards to hypoglyc-
emic episodes, gastrointestinal side effects, other adverse events, 
clinical laboratory abnormalities, and physical examinations was 
evaluated.
SUBJECTS AND METHODS
Ethics
The protocol was reviewed and approved by an Institutional 
Review Board (IRB) before the study was initiated. This trial 
was conducted in accordance with regulations governing clinical 
trials including the US Code of Federal Regulations (CFR), Title 
21, Part 50; regulations governing IRBs, Title 21, Part 56; and the 
Declaration of Helsinki concerning medical research in humans. 
Additional governing regulations included US CFR Title 21, Part 54 
and US CFR Title 21, Part 312. This study was also conducted 
according to International Conference on Harmonization (ICH) 
Good Clinical Practices (GCP).
Subject information and consent  
Prior to entry into the study, the nature and risks of the study 
were reviewed with each subject. Each subject or each subject’s 
legal representative was given the opportunity to read the IRB-
approved consent form and to ask questions. 
Criteria for evaluation
The populations analyzed for efficacy endpoints were the 
intent-to-treat (ITT) population and the efficacy evaluable (EE) 
population. The population used to analyze safety parameters 
was identical to the ITT population. Analysis of demographic 
and baseline for the ITT, EE and Safety populations indicated 
no gross dissimilarities between the three D-tagatose dose 
groups. The majority of subjects in each of the treatment groups 
and populations were male, Asian, non-smoking, non-drinking, 
around 50 years of age, weighing approximately 150 lbs, with 
diet and exercise for control of their diabetes. Usage of allowable 
medications during the trial was also similar across the three 
treatment groups.
Primary Efficacy Endpoint: The primary endpoint for this 
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Phase 2 dose-ranging study was a decrease of ≥ 0.5% in HbA1c 
level after 6 months of the study treatment.
Secondary Efficacy Endpoints: Secondary endpoints for this 
study included assessment of the effects of D-tagatose on other 
glycemic control measurements. These measurements included 
the proportions of subjects at each visit who achieved a decrease 
in HbA1c of ≥ 0.5%; proportions of subjects at each visit who 
achieved a decrease in HbA1c level of ≥ 1%; change from baseline 
to each study visit in fasting blood glucose concentrations, 
and plasma lipids (triglycerides, low density lipoprotein, total 
cholesterol, and high density lipoprotein); changes in body 
weight; changes in body mass index; and change in insulin levels.
Safety: Descriptive statistics and by-subject data listings 
were prepared for all safety parameters. No inferential statistics 
were performed for safety parameters. Safety was assessed 
through the entire duration of the study, and in the event of an 
adverse event (AE) or serious adverse event (SAE), safety was to 
be monitored until the AE/SAE resolved, or until the AE/SAE was 
deemed chronic or stable by the investigator.
Study design and plan
This study was designed as a prospective, randomized, 
6-month, parallel dose-ranging trial in subjects with mild type 
2 diabetes who, at the time of randomization, were not taking 
any oral anti-diabetic or anti-hyperglycemic medication or 
parenteral anti-diabetic medication and were controlling their 
diabetes with diet and exercise alone. This Phase 2 parallel dose-
ranging trial was designed to evaluate the dose-response effect 
of minimal doses of D-tagatose (2.5, 5.0, or 7.5 g,TID) on glycemic 
control in subjects with type 2 diabetes, who had undergone an 
8-week run-in period of standardized diet and exercise. This 
8-week stabilization period was considered a sufficient duration 
of standardized diet and exercise to provide a homogenous 
population of subjects with type 2 diabetes. No active control 
group was utilized in the design as the study was intended as a 
dose-ranging trial. The data from this trial was not intended to 
provide evidence of equivalence or superiority to any currently 
marketed medication.  
A total of 112 subjects were planned to be randomized into 
the study (i.e., 34 subjects to each of three treatment groups: 
2.5 g, 5.0 g, and 7.5 g D-tagatose given orally, three times daily, 
immediately prior to meals). Eight weeks after screening and 
stabilization, qualified subjects were randomized to receive 
one of three doses of D-tagatose. All doses of D-tagatose were 
premixed with drinking water into a solution of 4 ounces per 
dose. The study design is depicted in Figure 1. 
At the initial visit (Visit 1) subjects were screened for 
eligibility for entering the study. Subjects who were eligible were 
those diabetic subjects treated solely with diet and exercise and 
who had mildly elevated HbA1c levels but were otherwise in good 
health and were not suffering from any serious complications 
of diabetes or any other significant concurrent disease. Subjects 
were not to be taking any medications for the treatment of 
type 2 diabetes. The screening visit consisted of each subject 
undergoing a review of their relevant medical history and a 
physical examination, both of these primarily aimed at finding any 
abnormalities related to complications of diabetes. Additionally, 
clinical laboratory testing (including comprehensive hematology, 
clinical chemistry, liver function tests, lipid profile, HbA1c levels 
and urinalysis) was performed. At the end of the screening visit, 
potentially eligible study subjects were instructed to follow a 
weight-maintaining diet and a daily exercise program under the 
supervision of the investigator. They were given a blank subject 
diary and a nutritional diary, and were scheduled for the second 
visit (Visit 2) after 8 weeks of stabilization. No study drug was 
distributed at the screening visit (Visit 1).
All subjects who were eligible were randomized during Visit 
2 which took place within 8 weeks (± 7 days) of Visit 1. This was a 
single-blind study, in which subjects were blinded to dose group. 
At Visit 2, prior to randomization, baseline procedures including 
a complete medical evaluation with a review of medical history 
changes since Visit 1 and a physical examination were performed 
on qualifying subjects. In addition, subjects had blood drawn for 
clinical laboratory testing and urinalysis.
Randomization was stratified by site and baseline HbA1c 
levels (< 7.5% or ≥ 7.5%) to obtain a balanced distribution 
of subjects across the three arms of the trial. In addition to a 
supply of study medication, subjects received a diary and diary 
completion instructions for recording side effects, intercurrent 
illnesses/symptoms, and concomitant medications.
For Visits 3 and 4, subjects returned to the clinic for diary 
assessment, blood tests, and study drug compliance assessment 
and dispensation of additional study drug. Each of these visits 
had a ± 7 day window. Subjects had blood drawn for clinical 
laboratory testing and urinalysis.
During the final visit (Visit 5), the diary and all used and 
unused medication packets were collected and all assessments 
conducted at Visits 3 and 4 were repeated. Additionally, a final 
physical examination was conducted. Subjects were instructed to 
return to their primary physician for subsequent diabetes care 
and follow-up. This visit had a ± 7 day window. The efficacy and 
safety measurements that were evaluated throughout the study 
are provided in the study schedule (Table 1). 
Figure 1 Study Schedule. Subjects underwent an 8-week run-in 
period of standardized diet and exercise to provide a homogenous 
population of subjects with type 2 diabetes prior to randomization 
into three treatment groups. Treatment lasted for 6 months. Total 
duration of the study for subjects was 24 weeks with five study visits 
during the trial.
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Visit 1 Screening Visit 2 Randomization
Visit 3 
Month 1
Visit 4 
Month 3
Visit 5 
End of Study
Subject Registration to Study X     
Inclusion and Exclusion Criteria X     
Informed Consent* X     
Physical Examination X X   X
Medical History/Update X X X X X
Record Concomitant Medications X X X X X
Record Adverse Events  X X X X
Hematology Panel X X X X X
Chemistry Panel† X X X X X
Liver Function Tests‡ X X X X X
Lipid Profile§ X X X X X
HbA1c levels X X X X X
Urinalysis Panel X X X X X
Dispense Study Drug  X X X  
Dispense diaries X X X X  
Compensation X X X X X
Collect empty study drug vials/packages   X X X
Collect completed subject diaries  X X X X
* Explained to and signed by subject
† SMA-18 (or equivalent), creatinine clearance, and insulin levels 
‡ Alanine transaminase (ALT), aspartate aminotransferase (AST), total bilirubin, alkaline phosphatase, total protein, and albumin
§ Total cholesterol, high-density lipoprotein (HDL),  low-density lipoprotein (LDL), and triglycerides
Table 1: Schedule of Events.
In the event a subject was discontinued for any reason, an 
attempt was to be made to keep the subject on the safety arm 
of the study. Study treatment for discontinued subjects was to 
be stopped but the subject was to continue with the protocol 
assigned study visits but not the interim study drug supply visits. 
In the event the subject declined participation in the safety arm 
of the trial, after treatment discontinuation, Visit 5 (the End of 
Study Visit) was to be scheduled at least 30 days after the last 
dose.
Clinical Samples  
Blood samples used to assay HbA1c, blood glucose, insulin 
concentrations and lipids (total cholesterol, triglycerides, HDL, 
and LDL) were taken at each study visit, including the screening 
visit prior to the run-in period. All samples were collected and 
processed at the study center and then forwarded to the central 
laboratory (ICON Central Laboratories, Inc., Farmingdale, NY), by 
overnight courier, for assay.
Statistical Method
Three analysis populations were evaluated:
Intent-to-Treat (ITT) Population: The main efficacy analysis 
was conducted using the ITT Population. The ITT population 
included all subjects who had signed the study Informed Consent 
Form, received the protocol-specified treatment, and had a 
baseline and at least one post-baseline HbA1c value.
Efficacy Evaluable (EE) Population: The EE population was 
used for supportive analyses. The EE population consisted of all 
randomized subjects who completed treatment periods, received 
at least 80% of the study medication, and had no major protocol 
violations or eligibility violations. All protocol violations were to 
be identified prior to database lock.
Safety Population: The safety population was used for the 
analysis of safety variables. The safety population consisted of 
all randomized subjects who received at least one dose of study 
medication and had at least one post treatment visit of safety 
assessment.
Determination of Sample Size
The sample size calculation was based on a reduction of at 
least 0.5% in HbA1c level after 6 months of the study treatment 
compared to baseline for each dose group, a standard deviation 
of 1.0 for each treatment group, and an 80% statistical power 
with a two-sided analysis at a Type I error rate of 0.05. The 
required number of evaluable subjects was about 102 (34 for 
each D-tagatose dose group) based on nQuery Advisor, version 
6.01. A total of 40 subjects per treatment group (120 subjects for 
the study) were to be recruited, as it was expected to observe a 
15% drop out rate in this study population, and a total of 150 
subjects (50 for per treatment group) was screened based on the 
estimated screen failure rate of 20%.
Descriptive statistics and by-subject data listings were 
prepared for all efficacy parameters. For continuous data, 
summaries included number of observations, mean, standard 
deviation, median, minimum, and maximum values. For 
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categorical data, summaries included frequency counts and 
percentages. All statistical tests used in efficacy assessments 
were 2-sided, with no p-value adjustment. Data are presented as 
the mean ± standard deviation.
The primary efficacy variable was change in HbA1c level from 
baseline to 6 months. Baseline was defined as the last value 
obtained prior to the first randomized treatment. Changes from 
baseline HbA1c level were assessed using the general linear model 
(ANCOVA) to adjust for baseline differences and the stratification 
factor. Factors in the model included treatment and stratum of 
baseline HbA1c (< 7.5% or ≥ 7.5%). The least square means and 
standard error were derived from the general linear model for 
each dose group.
For secondary efficacy endpoints, (1) logistic regression was 
used to investigate the effect of treatment on the endpoint (i.e., 
decrease of ≥ 0.5% HbA1c reduction at each visit) and, decrease of 
≥ 0.5% HbA1c reduction at each visit, and (2) analysis of covariance 
(with stratification factor as covariate) was used to compare 
changes from baseline in fasting blood glucose, triglycerides, low 
density lipoprotein, total cholesterol, high density lipoprotein, 
body weight, body mass index, and insulin level.
RESULTS           
Study Population
The study evaluated the data from 18 clinical study sites (11 
sites in the United States and 7 sites in India) and 161 subjects 
were randomized to one of the three D-tagatose dosages (2.5 g: 
n = 57, 5.0 g: n = 51, and 7.5 g: n = 53). Of the 161 randomized 
subjects, 60 (37%) were withdrawn before completing the 
6-month treatment period. The most common reasons for 
withdrawal were subject request (18/161, 11%) and subject 
lost to follow up (11/161, 7%). The populations analyzed for 
efficacy endpoints were the ITT population (145 total; 52 in the 
2.5 g treatment group, 46 in the 5.0 g treatment group and 47 in 
the 7.5 g treatment group) and the EE population (87 total, 31 in 
the 2.5 g treatment group, 29 in the 5.0 g treatment group, and 
27 in the 7.5 g treatment group). The population used to analyze 
safety parameters was identical to the ITT population. There 
were no indicators of dissimilarity between the treatments in any 
of the analysis populations in terms of demographic or baseline 
characteristics, concomitant medication usage, or compliance 
with treatment, diet, or exercise.
Efficacy Results
Incidence of ≥ 0.5 HbA1c decrease after six months of 
treatment: Treatment success, as measured by the incidence of 
a 0.5 minimum HbA1c decrease from baseline after six months of 
treatment, was greatest for the 7.5 g TID dose of D-tagatose in 
both the ITT (25%, 12/47) and the EE (33%, 9/27) populations 
(see Figure 2). Treatment success, as measured by the primary 
endpoint (a reduction from baseline of 0.5 in HbA1c after six 
months of treatment) was greatest for the 7.5 g D-tagatose dose 
group, although the difference between the treatments was not 
statistically significant. For the 7.5 g dose group 25% of the 
population achieved this treatment success parameter compared 
to 19% in the 2.5 g dose group and 15% in the 5.0 g dose group. 
The difference across the three dose groups was not statistically 
Figure 2 Incidence of ≥ 0.5 HbA1c decrease after six months of 
treatment, ITT and EE populations. ANCOVA with baseline as 
covariate).
significant for either of the analysis populations (p > 0.05, logistic 
regression).
Incidence of ≥ 0.5 HbA1c decrease after one, three and 
six months of treatment: Incidence summaries of ≥ 0.5 HbA1c 
reduction from baseline after one, three, and six months of 
treatment for each of the D-tagatose dose groups are provided 
in Table 2 for the ITT population and in Table 3 for the EE 
population. Only the 7.5 g D-tagatose dose group indicated 
a dose-response trend over time; i.e., for the ITT population, 
treatment success was indicated for 4/47 (8%) after one month 
of treatment, for 5/47 (11%) after three months of treatment, 
and 12/47 (25%) after six months of treatment. For the EE 
population, success was indicated for 2/27 (7%) at the one and 
three month treatment time points and for 9/27 (33%) subjects 
at the six month time point. By logistic regression, the incidences 
across the three treatments at a single time point were not 
statistically significantly different.
Effect of D-tagatose on HbA1c values: The mean HbA1c 
D-tagatose 2.5g D-tagatose 5.0g D-tagatose 7.5g
Treatment 
Duration
N = 51
n (%)
N = 46
n (%)
N = 47
n (%)
One Month 8 (15.38%) 9 (19.57%) 4 (8.51%)
Three Months 11 (21.15%) 8 (17.39%) 5 (10.64%)
Six Months 10 (19.23%) 7 (15.22%) 12 (25.53%)
N = denominator for all percentages
Table 2: Incidence of ≥ 0.5 HbA1c decrease from baseline after one, three 
and six months of treatment, ITT population.
D-tagatose 2.5g D-tagatose 5.0g D-tagatose 7.5g
Treatment 
Duration
N = 31
n (%)
N = 29
n (%)
N = 27
n (%)
One Month 6 (19.35%) 7 (24.14%) 2 (7.41%)
Three Months 9 (29.03%) 8 (27.59%) 2 (7.41%)
Six Months 7 (22.58%) 6 (20.69%) 9 (33.33%)
N = denominator for all percentages
Table 3: Incidence of ≥ 0.5 HbA1c decrease from baseline after one, three 
and six months of treatment, EE population.
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levels for the three D-tagatose groups after 1, 3 and 6 months 
of treatment for the ITT and the EE populations are depicted in 
Figures 3A and 3B, respectively. For both analysis populations, 
a dose-response trend was observed for the 5.0 g and 7.5 g 
D-tagatose doses after 3 months and 6 months of treatment. 
Statistically, significant differences between the doses, however, 
were not achieved at any of the post-treatment time points (p > 
0.5, ANCOVA with baseline as covariate).
Reductions from baseline to six months in mean HbA1c were 
observed for the 5.0 g and the 7.5 g dose groups but not for the 
2.5 g dose group; i.e., mean baseline and 6-month values were 7.6 
± 0.66% and 7.6 ± 1.01%, respectively, for the 2.5 g dose group; 
7.4 ± 0.63% and 7.3 ± 0.85%, respectively, for the 5.0 g dose 
group; and 7.3 ± 0.60% and 7.1 ± 0.75%, respectively, for the 7.5 
g dose group (Figure 3B). These reductions indicate a positive 
dose response, although the differences in the observed mean 
reductions were not statistically significant between the three 
D-tagatose doses.
Effect of D-tagatose on fasting glucose values: For fasting 
glucose, only the 7.5 g dosage group exhibited reductions from 
baseline at the 3- and 6-month time points in both analyzed 
populations (ITT and EE, Figures 4A and 4B, respectively). For 
the EE population, baseline and 6-month means in fasting glucose 
were 130.4 ± 28.8 mg/dL and 136.3 ± 31.9 mg/dL, respectively, 
for the 2.5 g treatment; 129.5 ± 24.0 mg/dL and 131.2 ± 26.3 mg/
dL, respectively, for the 5.0 g treatment; and 136.7 ± 22.8 mg/dL 
and 123.1 ± 17.1 mg/dL, respectively, for the 7.5 g treatment (p 
= 0.0268) (Figure 4B). For the ITT and the EE populations, the 
7.5 g D-tagatose dose group provided a mean reduction in fasting 
glucose level after six months of treatment. 
Incidence of decreases in fasting glucose levels: Results 
indicate a dose-response trend for the incidence of fasting glucose 
decreases at 6 months in both the ITT and the EE populations. For 
the ITT population, the incidences of fasting glucose decreases 
after six months of treatment were 45% (21/47), 39% (18/46), 
and 36% (19/52) for the 7.5 g, 5.0 g, and 2.5 g D-tagatose 
treatment groups, respectively. For the EE population, the 
incidences of glucose decreases were 70% (19/27), 55% (16/29), 
and 42% (13/31), respectively. These data are depicted in Figure 
5. No statistically significant differences across the treatments (p 
> 0.5, logistic regression) were observed for either population at 
any of the post treatment time points.
Effect of D-tagatose on serum insulin: The mean insulin 
levels (µIU/mL) for the three D-tagatose dose groups after 1, 
3 and 6 months of treatment and the two analysis populations 
are depicted in Figure 6. For both analysis populations, the 7.5 
g D-tagatose dose group showed consistent reductions from 
the mean baseline insulin level after three and six months of 
treatment. For the ITT population (Figure 6A), the 7.5 g D-tagatose 
dose group demonstrated a mean baseline insulin level of 8.5 
± 8.2 µIU/mL; and after three and six months of treatment the 
mean insulin levels for this dose group were 7.3 ± 7.0 µIU/mL 
and 5.0 ± 3.6 µIU/mL, respectively. For the EE population (Figure 
Figure 3 Effect of D-tagatose on mean HbA1c values after 1, 3, and 6 
months of treatment, ITT population (A) and EE population (B). Data 
are presented as the mean ± standard deviation.
Figure 4 Effect of D-tagatose on mean fasting glucose values after 1, 3, 
and 6 months of treatment, ITT (A) and EE (B) populations. Data are 
presented as the mean ± standard deviation.
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Figure 5 Effect of D-tagatose on the incidence of fasting blood sugar 
(i.e., glucose) decreases after 1, 3, and 6 months of treatment, ITT (A) 
and EE (B) populations.
Figure 6 Effect of D-tagatose on mean insulin values after 1, 3, and 
6 months of treatment, ITT (A) and EE (b) populations. Data are 
presented as the mean ± standard deviation.
6B), the 7.5 g D-tagatose dose group demonstrated a mean 
baseline insulin level of 9.1 ± 10.6 µIU/mL; and after three and 
six months of treatment the mean insulin levels for this dose 
group were 7.2 ± 7.7 µIU/mL and 5.1 ± 3.4 µIU/mL, respectively. 
Statistically significant differences between the doses, however, 
were not achieved at any of the post-treatment time points (p > 
0.5, ANCOVA with baseline as covariate) for either the ITT or the 
EE populations.
Effect of D-tagatose on lipids: No statistically significant 
differences between treatments at any measured time point were 
observed for total, LDL, or HDL cholesterol measurements (data 
not shown); and all dosages provided some measure of reduction 
from mean baseline values at one or more time points. There 
was a striking elevation in mean triglyceride level after three 
months of treatment with the 5.0 g D-tagatose dose group in both 
ITT and EE populations (Figure 7). For the ITT population, the 
mean triglyceride concentrations at baseline and three months 
for the 5.0 g dose were 181 ± 92.7 mg/dL and 218 ± 149 mg/
dL, respectively; 162 ± 89.8 mg/dL and 179 ± 93.4 mg/dL, 
respectively, for the 2.5 g dose; and 179 ± 99.8 mg/dL and 165 
± 74.7 mg/dL, respectively, for the 7.5 g dose. The difference 
between the treatment groups at the 3-month time point was 
statistically significant in the ITT population (p = 0.0296, ANCOVA 
with baseline as covariate).  Similar results were observed with 
the EE population; however the difference between treatments 
at three months was not statistically significant with the EE 
population. 
Effect of D-tagatose on body weight: Mean body weights, 
over time, reduced in a dose-response fashion, with the 5.0 g 
and the 7.5 g D-tagatose doses providing the greatest reductions 
(Figure 8). Mean body weights at baseline, 3-months, and 
6-months for the 5.0 g D-tagatose dose group were 165.4 ± 33.0 
lbs, 161.5 ± 29.5 lbs, and 161.7 ± 27.5 lbs, respectively; and the 
mean body weights for the 7.5 g D-tagatose dose group were 167.4 
± 33.0 lbs, 165.1 ± 30.5 lbs, and 160.6 ± 29.3 lbs, respectively. The 
mean body weights for the 2.5 g D-tagatose dose group and the 
EE population remained within 1 lb of mean baseline weight at 
all post baseline time points. There was a statistically significant 
difference between the mean weights of the three treatments 
at the 3-month time point for the EE population (p = 0.0345, 
ANCOVA with baseline as covariate).
Safety results: D-tagatose at all doses was well-tolerated. 
None of the reported adverse events were unexpected and 
the majority was of a gastrointestinal nature, as expected. The 
incidences of all reported events were similar for all treatments. 
There were no disparities between the three treatments in any 
of the assessed safety parameters. Nearly all reported AEs were 
of mild or moderate severity. Severe AEs occurring during the 
study are summarized in Table 4. There did not appear to be a 
dose-response relationship in terms of AE severity. As expected, 
the highest incidences of probably or possibly related AEs 
were gastrointestinal disorders. No dose-response trends were 
observed for any of the AEs that were assessed as possibly or 
probably related to study treatment.
Disposition of subjects: The study disposition of randomized 
subjects is provided in Table 5. One hundred and sixty one (161) 
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Figure 7 Effect of D-tagatose on mean triglyceride values after 1, 3, 
and 6 months of treatment, ITT (A) and EE (B) populations. Data are 
presented as the mean ± standard deviation.
Figure 8 Effect of D-tagatose on mean body weight after 1, 3, and 
6 months of treatment, ITT (A) and EE (B) populations. Data are 
presented as the mean ± standard deviation.
subjects were randomized and analyzed. Of the 161 randomized 
subjects, 57/161 (35%) were randomized to the 2.5 g dose 
group, 51/161 (32%) were randomized to the 5.0 g dose group, 
and 53/161 (33%) were randomized to the 7.5 g dose group.
All treatment groups had a median study medication 
compliance of approximately 80%, and full to good compliance 
with the study-mandated diet and exercise, as assessed by the 
investigator, was 77% to 87% after the first month, 70% to 79% 
after three months, and 63% to 74% after six months. Given the 
similarity of the treatment groups in terms of demographics, 
baseline characteristics, concomitant medication usage, and 
compliance with treatment, diet and exercise, the resulting 
efficacy and safety analyses were considered reliable for 
comparisons between three D-tagatose dose groups.
Sixty (60) randomized subjects (37.3%) were withdrawn 
before completing the 6-month treatment period. Two 
subjects, from each of the dose groups were withdrawn prior 
to receiving the first dose of study medication, resulting in a 
similar withdrawal rate for each of the three doses. However, 
when individual reasons for withdrawal were evaluated, two 
interesting dose-response trends were noted: one for subject-
initiated withdrawals and one for withdrawals due to AEs/SAEs 
(Table 6). 
Subject-initiated withdrawals: Of the randomized subjects, 
18.0% (29/161) were withdrawn due to subject request or 
lost to follow up. The highest incidence for these two reasons, 
D-tagatose 2.5g
N = 52
n (%)
D-tagatose 5.0g
N = 46 
n (%)
D-tagatose 7.5g
N = 47 
n (%)
Total
N = 145 
n (%)
Nausea - - 1 (2.1%) 1 (0.7%)
Retching - - 1 (2.1%) 1 (0.7%)
Vomiting 1 (1.9%) - - 1 (0.7%)
Fatigue - 1 (2.2%) - 1 (0.7%)
Lethargy - 1 (2.2%) - 1 (0.7%)
Anxiety 1 (1.9%) - - 1 (0.7%)
Table 4: Incidence of severe adverse events, safety population.
D-tagatose 
2.5g
D-tagatose 
5.0g
D-tagatose 
7.5g Total
Number 
Randomized (N)* 57 51 53 161
n (%) n (%) n (%) n (%)
Received  ≥ 1 Dose 55 (96.5%) 49 (96.1%) 51 (96.2%) 155 (96.3%)
Completed Study† 35 (61.4%) 32 (62.7%) 34 (64.2%) 101 (62.7%)
Withdrawn 22 (38.6%) 19 (37.3%) 19 (35.8%) 60 (37.3%)
*Denominator for all percentages. 
†Completed study through the end of the 6-month treatment period
Table 5: Study Disposition of Randomized Subjects.
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combined, was with the 7.5 g dose group; i.e., 6/57 (10.5%) in 
the 2.5 g dose group, 8/51 (15.7%) in the 5.0 g dose group, and 
15/53 (28.3%) in the 7.5 g dose group (Table 6). These data 
suggest that as the dosage increased so did the drop-outs due to 
“subject request” and “lost to follow-up,” combined (i.e., subject-
initiated withdrawals).  This observation is supported by the fact 
that, when the two reasons (subject request and lost to follow-up) 
were analyzed separately, each of the responses also indicated a 
positive dose-response.  These results all appear to indicate that 
as the dosage increased, so did the incidence of subject-initiated 
withdrawals.
Withdrawals due to AEs/SAEs: The incidence of 
withdrawals due to AEs and SAEs for all dose groups combined 
was 8/161 (5.0%) with what appears to be an inverse dose-
response relationship; i.e., as the dosage increased the incidence 
of withdrawals due to AEs decreased.  The highest incidence 
of withdrawals due to AEs was in the 2.5 g dose group (5/57, 
8.8%) and the lowest incidence of withdrawals due to AEs was 
in the 7.5 g group (1/53, 1.9%) (Table 6).  Withdrawals due to 
protocol deviations were less than 5% for all doses, combined. 
The individual dose groups all had similar incidences, ranging 
from approximately 4% to approximately 5%.
DISCUSSION
This dose-ranging trial was conducted to evaluate the effect of 
three doses of D-tagatose (2.5 g, 5.0 g, and 7.5 g), taken three times 
daily over a period of six months, on various glycemic control 
measures and safety parameters in type 2 diabetic patients.  In 
this trial, the 5.0 g TID dose of D-tagatose was assumed (based on 
previous trials [7]) to be a minimally effective dose in reducing 
HbA1c, a primary measurement of glycemic control.  The 2.5 g tid 
dose of D-tagatose (which served as a nominal-effect comparator) 
and the 7.5 g tid dose were selected to bracket the 5.0 g tid dosage 
level.
The efficacy parameters selected for evaluation in this 
trial are all common measures of glycemic control for diabetic 
patients:  HbA1c, fasting glucose levels, lipid parameters, blood 
insulin levels, and body weight. The primary efficacy parameter 
selected for this trial was a dichotomous variable: the treatment 
success as measured by a reduction from baseline HbA1c by at 
least 0.5 units after six months of treatment (i.e., 0.5% reduction 
in HbA1c after six months of treatment). Dichotomous variables, 
by nature, are not the most sensitive metric by which to assess 
treatment differences; nevertheless, a treatment difference was 
noted in that 12/47 (26%) of the 7.5 g D-tagatose dose group 
(ITT population) and 9/27 (33%) EE population in the dose 
groups met the endpoint (Tables 2 and 3).  For both populations, 
of the three studied dosages, the 7.5 g D-tagatose dose exhibited 
the greatest incidence of success, as measured by this parameter. 
Interestingly, a dose response was not observed in the primary 
endpoint. For the ITT population and the primary endpoint, the 
2.5 g and the 5.0 g D-tagatose doses had a success incidences of 
10/52 (19%) and 7/46 (15%), respectively and the difference 
between the three dosages were not statistically significant. 
Similar results for the lower doses were observed with the 
EE population.  Continuous variables are traditionally more 
sensitive in detecting differences between treatments. Mean 
HbA1c reductions after six months of treatment within the ITT 
population were greatest for the 7.5 g D-tagatose group (Figure 
3A). The minimum dosage at which HbA1c reductions were 
evident was the 5.0 g tid dosage. The mean baseline and the mean 
6-month HbA1c values for the 2.5 g treatment group remained the 
same. The differences between the treatment groups in HbA1c 
measurements were not statistically significant at any post 
treatment time point. Similar results with HbA1c reduction were 
observed with the EE population (Figure 3B). 
Regarding fasting glucose mean values and mean changes 
from baseline over time, a reduction from baseline was observed 
only in the 7.5 g D-tagatose dose group, beginning after three 
months of treatment with increasing reduction at the 6-month 
time point, at which time statistical significance was observed 
(Figure 4), thereby supporting the analysis of the primary 
endpoint. Additionally, for the EE population, the incidence 
rates of subjects achieving any decrease in fasting glucose values 
indicated consistent increases throughout the treatment period 
for the 7.5 g dose group, although the differences across the 
groups was not statistically significant at any time point. This 
observation provided further support of the primary endpoint 
results. The observed increases and reductions in fasting glucose 
levels over time for the 2.5 g and the 5.0 g treatments are most 
likely due to the inherent variability of the fasting glucose 
parameter. 
Reason for Withdrawal
D-tagatose 2.5g
N = 57
n (%)
D-tagatose 5.0g
N = 51
n (%)
D-tagatose 7.5g
N = 53
n (%)
Total
N = 161
n (%)
Subject Request 3 (5.3%) 5 (9.8%) 10 (18.9%) 18 (11.2%)
Lost to Follow-up 3 (5.3%) 3 (5.9%) 5 (9.4%) 11 (6.8%)
AE/SAE 5 (8.8%) 2 (3.9%) 1 (1.9%) 8 (5.0%)
Protocol Deviation 3 (5.3%) 2 (3.9%)* 2 (3.8%) 7 (4.3%)
Termination by Sponsor 2 (3.5%) 0 (0.0%) 0 (0.0%) 2 (1.2%)
Other 6 (10.5%)† 7 (13.7%) 1 (1.9%) 14 (8.7%)
Total Withdrawn 22 (38.6%) 19 (37.3%) 19 (35.8%) 60 (37.3%)
N = Randomized subjects; denominator for all percentages
*One randomized subject in this dose group had a recorded reason for withdrawal of “screen failure” and was therefore tabulated with those 
withdrawn for a protocol deviation
†One randomized subject in this dose group had no reason for withdrawal specified on the CRF  and was therefore tabulated with “Other” 
Table 6: Reasons for Withdraw, Randomized Subjects.
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Each of the doses had some measure of mean insulin reduction 
at one or more post-baseline time points in both analyzed 
populations. After six months of treatment, however, only the 5.0 
g and the 7.5 g dosages had mean levels that were lower than that 
of baseline (Figure 6A). There were no statistically significant 
differences between treatments at any of the measured time 
points.  Similar results were observed with the EE population 
(Figure 6B).  
No statistically significant difference between treatments 
at any measured time point was observed for total, LDL, or 
HDL cholesterol measurements; and all dosages provided some 
measure of reduction from mean baseline values at one or more 
time points. There was a striking elevation in mean triglyceride 
level after three months of treatment with the 5.0 g D-tagatose 
dose group in both the ITT and the EE populations (Figure 7). This 
rise in triglycerides at the 5.0 g dose warrants further research.  
Mean body weights, over time, were reduced in a positive 
dose-response fashion, with the 5.0 g and the 7.5 g D-tagatose 
doses providing the greatest reductions (Figure 8).  The mean 
body weights for the 2.5 g D-tagatose dose group remained within 
1 lb of mean baseline weight at all post baseline time points.
D-tagatose at all doses was well tolerated. None of the 
reported adverse events were unexpected and the majority was 
of a gastrointestinal nature, as expected. The incidences of all 
reported events were similar for all treatments. Finally, there 
were no disparities between the three treatments in any of the 
assessed safety parameters. 
Although not always statistically significant, the high dose 
(7.5 g tid of D-tagatose) appeared to provide the greatest efficacy 
of the three tested doses in terms of incidence rates achieving 
≥ 0.5% decrease in HbA1c, reductions in fasting glucose values, 
reductions in lipid parameters, reduction in insulin concentration, 
and reduction in body weight. Additionally, it appears that 5.0 g 
tid of D-tagatose was the minimally effective dose for providing 
reduction in glycemic measures within this type 2 diabetic 
population.
Future research might investigate the inverse dose-response 
relationships for constipation, nausea, headache, vomiting, and 
eructation (Table 6).
CONCLUSIONS
Several points can be concluded from this study designed to 
determine the minimum dose of D-tagatose required to
 • D-tagatose at 5.0 g tid was the minimal dose required to 
reduce HbA1c.
 • D-tagatose at 7.5 g tid provided the greatest effect in most 
measured efficacy parameters.
 • Future research might investigate the elevation of mean 
triglycerides with the 5.0 g D-tagatose dose group after 
three months of treatment.  However, this elevation was 
transient and did not appear at the 6 month timepoint. 
This elevation was also only observed in the ITT 
population.  If it were a drug effect, it would also likely 
appear in the EE population.
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